At a glance
- Originator National Institutes of Health (USA); Vanderbilt University
- Developer SciClone Pharmaceuticals
- Class Neuroprotectants; Small molecules; Xanthines
- Mechanism of Action Adenosine A1 receptor antagonists
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
Highest Development Phases
- Discontinued Cystic fibrosis
Most Recent Events
- 29 Mar 2001 CPX has received orphan drug status for cystic fibrosis in the European Union
- 10 Nov 2000 CPX has been re-formulated for further phase II studies
- 12 May 1999 Cystic Fibrosis Foundation awards SciClone $US517 000 research grant